Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

NCT00513578 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

BIOLOGICAL: PR1 leukemia peptide vaccine
BIOLOGICAL: incomplete Freund's adjuvant
BIOLOGICAL: sargramostim

Sponsor

The Vaccine Company